focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 488.00
Bid: 488.00
Ask: 495.00
Change: 0.00 (0.00%)
Spread: 7.00 (1.434%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 488.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

High-performance foam in medical facility doors

27 Apr 2023 07:00

RNS Number : 6037X
Zotefoams PLC
27 April 2023
 

27 April 2023

Zotefoams plc

("Zotefoams" or "Group")

 

Agreement to supply high-performance foam for use in medical facility doors

Zotefoams, a world leader in cellular materials technology, is pleased to announce an agreement with Kennon Products (Wyoming, USA) to supply ZOTEK® F high-performance foam for use in Kennon's newest ligature-resistant patient safety door, broadening the scope of application for this material. So-called breakaway doors are used in medical facilities to protect vulnerable patients from self-harm while affording privacy.

Produced exclusively by Zotefoams and manufactured from PVDF (polyvinylidene fluoride), ZOTEK F is best-known as a disruptive material that has enabled airframe manufacturers and airlines to reduce carbon consumption by shedding significant weight from aircraft interiors. Equally important are the safety credentials of the material: PVDF is inherently inert, and Zotefoams' proprietary method of foam manufacture does not affect that essential purity. Accordingly, ZOTEK F achieves the highest ratings for its Fire, Smoke and Toxicity (FST) properties and also exhibits excellent resistance to mould and bacteria growth.

Safety is the foremost consideration in the design of the Kennon Door 2.0. The softness of ZOTEK F and its light weight combine with breakaway magnetic hinges to save lives, as do its resistance to flame and - in the event of ignition - low smoke output. The durable design of the door also enhances the look of any facility.

Kennon achieved its primary objective, that of developing a door that achieves the USA's new National Fire Protection Association NFPA-286 certification, which is required for facility operators wishing to meet certain fire prevention guidelines.

"The unique properties of ZOTEK F foam are a key reason for our anti-ligature doors meeting the NFPA-286 standard," said Kennon CEO, Joe Wright. "Our partnership with Zotefoams has been a mutual success and together we're helping to save lives in behavioural health hospitals."

David Stirling, Zotefoams Group CEO, commented, "We were pleased to work closely with Kennon on this project, selecting and testing various ZOTEK F materials, while providing support and insight based on our previous experience of aviation applications and flame testing.

"This application has produced another 'first' for ZOTEK F and demonstrates the potential of the material to deliver benefits well beyond its current core markets of aviation and aerospace."

* ENDS *

 

 

Enquiries:

 

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

 

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA, Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

 

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAIFMFTMTATBBJ
Date   Source Headline
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
12th Aug 20221:43 pmRNSDirector/PDMR Shareholding
11th Aug 20223:50 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSInterim Results
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
20th Jul 20224:42 pmRNSSecond Price Monitoring Extn
20th Jul 20224:36 pmRNSPrice Monitoring Extension
12th Jul 202212:39 pmRNSDirector/PDMR Shareholding
8th Jul 20227:00 amRNSNotice of Results
30th Jun 20224:52 pmRNSDirector/PDMR Shareholding
8th Jun 20224:40 pmRNSSecond Price Monitoring Extn
8th Jun 20224:35 pmRNSPrice Monitoring Extension
8th Jun 20228:49 amRNSDirector/PDMR Shareholding
26th May 20224:41 pmRNSSecond Price Monitoring Extn
26th May 20224:36 pmRNSPrice Monitoring Extension
25th May 20221:04 pmRNSResult of the 2022 Annual General Meeting
25th May 20227:00 amRNSTrading Update
18th May 20224:41 pmRNSSecond Price Monitoring Extn
18th May 20224:36 pmRNSPrice Monitoring Extension
12th May 20223:58 pmRNSDirector/PDMR Shareholding
11th May 20222:13 pmRNSDirector/PDMR Shareholding
25th Apr 20225:16 pmRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNS2021 Annual Report and Notice of the 2022 AGM
11th Apr 20223:49 pmRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSPreliminary Results
14th Mar 202212:30 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSNotice of results and investor presentation
15th Feb 20224:26 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSFull Year Trading Update
12th Jan 202211:12 amRNSDirector/PDMR Shareholding
23rd Dec 20211:56 pmRNSDirector/PDMR Shareholding
17th Dec 20217:00 amRNSTrading Update
14th Dec 202111:55 amRNSDirector/PDMR Shareholding
12th Nov 202112:41 pmRNSDirector/PDMR Shareholding
10th Nov 20215:48 pmRNSHolding(s) in Company
4th Nov 20215:59 pmRNSHolding(s) in Company
4th Nov 20213:31 pmRNSDirector/PDMR Shareholding
3rd Nov 20217:00 amRNSQ3 Trading Update
15th Oct 202112:10 pmRNSDirector/PDMR Shareholding
12th Oct 202111:05 amRNSDirector/PDMR Shareholding
1st Oct 20213:31 pmRNSHolding(s) in Company
14th Sep 202110:05 amRNSDirector/PDMR Shareholding
12th Aug 20212:28 pmRNSDirector/PDMR Shareholding
10th Aug 20217:00 amRNSInterim Results
19th Jul 20219:26 amRNSNotice of Results
13th Jul 20211:59 pmRNSDirector/PDMR Shareholding
14th Jun 20213:06 pmRNSDirector/PDMR Shareholding
14th Jun 202111:35 amRNSDirector/PDMR Shareholding
10th Jun 20214:41 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.